Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody Cocktail

Inclusion Criteria: 1. Subject provides written informed consent prior to initiation of any study procedures. 2. Understands and agrees to comply with planned study procedures. 3. Adult ≥18 years of age at time of enrollment, pediatric ages will be excluded. 4. Subject consents to receiving a COVID-19 positive organ (kidney, liver, or heart) a. Deceased immunocompetent donor with positive SARS-CoV-2 RT-PCR testing from the respiratory tract (upper or lower): i. Within 21 days since the date of COVID-19 diagnosis OR ii. Within 90 days since the date of COVID-19 diagnosis 5. Subject is confirmed COVID-19 negative confirmed by PCR at time of transplant with no signs and symptoms consistent with COVID-19 6. All candidates must be fully vaccinated 2 weeks prior to enrollment a. When applicable candidates can receive a booster vaccine as defined by the FDA/CDC Exclusion Criteria: 1. Any exposure to investigational medications targeting COVID-19 2. Previous use of casirivimab with imdevimab antibody cocktail (REGEN-COV) 3. Previous treatment of COVID-19 with a monoclonal antibody 4. Active COVID-19 infection 5. Allergy to casirivimab with imdevimab 6. Pregnant patients 7. Prior transplant 8. Hepatitis C virus/NCT positive deceased donors